Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland.
The FDA has approved MSD’s oral HIF-2 alpha inhibitor Welireg for a second cancer indication, relapsed or refractory advanced renal cell carcinoma (RCC), the most common f
Scotland has become the first country in Europe to recommend coverage of MSD’s Welireg as a treatment for some people with von Hippel-Lindau disease (VHL), a rare genetic
Merck & Co has extended its range of cancer medicines in the US after claiming FDA approval for Welireg – a drug it acquired as part of its $2.2 billion takeover of Peloton Therapeutics
Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially.